QDEL — QuidelOrtho Corp

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1906324 ·
Last close
$11.99
Market Cap
$817.61M
52W High
$22.76
52W Low
$9.92
ADV30
2,786,212
Next earnings
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 619,800,000 263,800,000 -27,400,000 -91,800,000 5,628,700,000 140,400,000 3,777,300,000
Dec 2025 723,600,000 320,400,000 -37,300,000 -130,700,000 5,769,300,000 169,800,000 3,848,800,000
Sep 2025 699,900,000 335,600,000 45,200,000 -733,000,000 5,675,100,000 98,100,000 3,638,700,000
Jun 2025 613,900,000 274,900,000 -1,800,000 -255,400,000 6,379,100,000 151,700,000 3,586,400,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$6,600,000
Investing CF
$-170,500,000
Financing CF
$175,800,000
CapEx
$-166,000,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-17.82
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,087,800,000
Inventory
$611,500,000
Receivables
$486,700,000
ST Investments
$0
EBIT TTM
$-989,600,000
Pretax Income TTM
$-1,178,400,000
Interest Exp TTM
$188,800,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,657,200,128
EBITDA
$491,700,000
Free Cash Flow
$208,575,008
Enterprise Value
$3,543,045,120
Total Cash
$140,400,000
Total Debt
$2,874,700,032
Shares Out
68,190,989
Trailing EPS
$-17.86
Book Value
$27.19
ROE
-49.9%
ROA
0.5%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,730,200,000 54,800,000 -1,131,800,000 5,769,300,000 3,848,800,000 105,200,000
Dec 2024 2,782,900,000 45,800,000 -2,052,000,000 6,423,600,000 3,439,100,000 83,000,000
Dec 2023 2,997,800,000 257,000,000 -10,100,000 8,563,100,000 3,557,200,000 280,200,000
Dec 2022 3,266,000,000 982,500,000 548,700,000 8,855,800,000 3,921,200,000 885,300,000
Dec 2021

TTM Snapshot

Revenues TTM
$2,764,700,000
NetIncome TTM
$202,300,000
OpCashFlow TTM
$0
Assets (Latest)
$6,423,600,000
Forward EPS
$2.44

Peers — same industry

TickerNameMarket CapLastDaily %
ABSI Absci Corp $823.18M $5.28
ACHV ACHIEVE LIFE SCIENCES, INC. $468.13M $4.56
NNNN Anbio Biotechnology $1.45B $33.01
NRC NRC HEALTH $429.10M $19.04
NTLA Intellia Therapeutics, Inc. $1.76B $12.61

News headlines (Yahoo Finance, 1h cache)

When Blood Compatibility Becomes a Pregnancy Risk
2026-05-21 13:18 · Yahoo
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
2026-05-20 11:00 · Yahoo
5 Insightful Analyst Questions From QuidelOrtho’s Q1 Earnings Call
2026-05-15 16:52 · Yahoo
Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls
2026-05-07 13:45 · Yahoo
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
2026-05-06 16:16 · Yahoo
QuidelOrtho Q1 Earnings Call Highlights
2026-05-06 02:07 · Yahoo
QuidelOrtho Corporation Q1 2026 Earnings Call Summary
2026-05-06 00:20 · Yahoo
QuidelOrtho (QDEL) Q1 2026 Earnings Transcript
2026-05-05 22:39 · Yahoo
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates
2026-05-05 22:05 · Yahoo
QuidelOrtho (NASDAQ:QDEL) Misses Q1 CY2026 Revenue Estimates
2026-05-05 20:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.